Please assess the completion status of the following clinical trial:

Trial Title: Re-examination Study For Varivax (V210-059 AM2)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants must be vaccinated with VARIVAX as a standard of care~Exclusion Criteria:~* Participants who have been previously vaccinated with VARIVAX~* Contraindication with VARIVAX

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- VARIVAX (Type: None): Attenuated live varicella vaccine was administered in usual practice. Recommended dosing is a single 0.5 mL subcutaneous injection in children 12 months to 12 years of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).